CHLAMYDIA IN-OFFICE RAPID DIAGNOSTIC ASSAYS
This article was originally published in The Gray Sheet
CHLAMYDIA IN-OFFICE RAPID DIAGNOSTIC ASSAYS lack sufficient sensitivity to ensure treatment of asymptomatic women with Chlamydia infections, Edward Book, MD, University of Alabama Department of Medicine, Birmingham, et al. conclude in a study published in the Sept. 21 Journal of the American Medical Association. Noting the 48.5% sensitivity rate seen with the rapid Chlamydia assay in the study, the authors point out that the rapid test, "had it been used exclusively for Chlamydia screening, would have resulted in treatment for less than half of all women with culture-proven infections."
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.